Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome

Chen, Chiung-Nien; Hsieh, Fon‐Jou; Cheng, Yung-Ming; Lee, Po‐Huang; Chang, King‐Jen

doi:10.1002/jso.20037

Cited by 44 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased expression of eIF4E is associated with increasing grade of disease (19)(20)(21)(22)(23)(24)(25)(26). Furthermore, elevated total eIF4E levels along with 4EBP1 hyperphosphorylation, which increases the availability of eIF4E to bind with eIF4G and enhance cap-dependent translation, have been observed in both breast cancer and prostate cancer and correlate with both decreased progression-free and overall survival (19,20).…”

Section: Clinical Relevance Of Eif4e In Human Cancersmentioning

confidence: 99%

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer

Hsieh

Ruggero

2010

Clinical Cancer Research

165

150

View full text Add to dashboard Cite

Recent advances in understanding the role of eukaryotic translation initiator factor 4E (eIF4E) in tumorigenesis and cancer progression have generated significant interest in therapeutic agents that indirectly or directly target aberrant activation of eIF4E in cancer. Here, we address the general function of eIF4E in translation initiation and cancer, present evidence supporting its role in cancer initiation and progression, and highlight emerging therapeutics that efficiently target hyperactivated eIF4E. In doing so, we also highlight the major differences between these therapeutics that may influence their mechanism of action.

show abstract

Section: Clinical Relevance Of Eif4e In Human Cancersmentioning

confidence: 99%

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer

Hsieh

Ruggero

2010

Clinical Cancer Research

165

150

View full text Add to dashboard Cite

show abstract

“…This was the first component of the translation initiation machinery known to cause deregulated cell growth and malignant transformation (Lazaris-Karatzas et al, 1990). eIF4E is overexpressed in a broad spectrum of human tumors, such as bladder, head and neck, liver, colon, bronchioalveolar and breast cancer (for a complete review, see Ruggero and Pandolfi, 2003;De Benedetti and Graff, 2004;Mamane et al, 2006; Figure 3), conferring to eIF4E the status of a valuable prognostic marker (Chen et al, 2004;Byrnes et al, 2006;Zhou et al, 2006). This overexpression is thought to be caused by gene amplification, at least in head and neck cancer and breast cancer (Sorrells et al, 1999;Haydon et al, 2000).…”

Section: Alterations Of the Eif4f Complex Componentsmentioning

confidence: 99%

Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies

Bilanges

Stokoe

2007

Oncogene

View full text Add to dashboard Cite

“…Previous research proved that eIF4E plays a pivotal role in cell growth, survival, invasion, EMT and angiogenesis, and that it promotes tumorigenesis, metastasis, and recurrence in numerous cell and animal models 24. Overexpression of eIF4E was reported in many types of cancers, suggesting it as a diagnostic marker and therapeutic target 25. EIF4E activity is regulated by the PI3K/Akt/mTOR/4E‐BP1, MEK/ERK/Mnk and p38 MAP kinase pathways 26, 27.…”

Section: Introductionmentioning

confidence: 99%

AEG‐1 induces gastric cancer metastasis by upregulation of eIF4E expression

Yang

et al. 2017

J Cellular Molecular Medi

View full text Add to dashboard Cite

Gastric cancer is the third leading cause of cancer‐related deaths worldwide, and patients with lymph node, peritoneal and distant metastasis have a poor prognosis. Overexpression of Astrocyte‐elevated gene‐1 (AEG‐1) has been reported to be correlated with the progression and metastasis of gastric cancer. However, its mechanisms are quite unclear. In this study, we found that elevated expression of AEG‐1 was correlated with metastasis in human gastric cancer tissues. Moreover, gain‐ or loss‐of‐function of AEG‐1, respectively, promoted or suppressed epithelial–mesenchymal transition (EMT), migration and invasion of gastric cancer cells. AEG‐1 positively regulated eIF4E, MMP‐9 and Twist expression. Manipulating eIF4E expression by transfection of overexpression constructs or siRNAs partially eliminated AEG‐1‐regulated EMT, cell migration and invasion. In addition, overexpression or knockdown of eIF4E promoted or suppressed EMT, cell migration and invasion in parallel with upregulation of MMP‐9 and Twist expression, while manipulating eIF4E expression partially abrogated AEG‐1‐induced MMP‐9 and Twist. Finally, silencing of AEG‐1 expression not only inhibited tumour growth in parallel with downregulation of eIF4E, MMP‐9 and Twist expression in a xenograft nude mouse model, but also suppressed lymph node and peritoneal metastasis of gastric cancer in an orthotopic nude mouse model. These findings suggest that AEG‐1 promotes gastric cancer metastasis through upregulation of eIF4E‐mediated MMP‐9 and Twist, which provides new diagnostic markers and therapeutic targets for cancer metastasis.

show abstract

Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome

Cited by 44 publications

References 20 publications

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer

Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies

AEG‐1 induces gastric cancer metastasis by upregulation of eIF4E expression

Contact Info

Product

Resources

About